Nanobiotix Launches $87M Global Follow-On Offering to Fund R&D
NBTX has more than doubled off its 52-week low of $3.64.
Summary
Nanobiotix has launched a global follow-on offering to raise approximately $87 million through ADSs, ordinary shares, and pre-funded warrants, with proceeds primarily funding R&D and general corporate purposes.
Key Events · Financing and Capital Events · NBTX
-
Global Follow-On Offering Launched
Nanobiotix has launched a global follow-on offering to raise approximately €75 million (around $87 million) through a public offering of American Depositary Shares (ADSs) in the U.S. and an offering of ordinary shares and pre-funded warrants (PFWs) in Europe.
-
Proceeds Allocated to R&D and Operations
The net proceeds will be used primarily for research and development, with less than 10% supporting JNJ-1900 (NBTXR3) development, 50-60% advancing Nanoprimer and other platforms, and 30-40% for general corporate purposes.
-
Pricing Determined by Book-Building
The final offering price will be determined through a book-building process, with ordinary shares priced at least equal to the volume-weighted average price (VWAP) over the last three trading sessions, subject to a maximum 15% discount.
-
Insider and Company Lock-Up
Executive board members, supervisory board members, and the company itself are subject to a 90-day contractual lock-up period following the pricing of the Global Offering, subject to customary exceptions.
Analysis · NBTX · Life Sciences
Nanobiotix has launched a significant global follow-on offering aiming to raise approximately €75 million (around $87 million). This capital raise, representing over 4% of the company's market capitalization, is crucial for a late-clinical stage biotechnology company like Nanobiotix, providing essential funding for the development and advancement of its JNJ-1900 (NBTXR3) program and other Nanoprimer platforms. While dilutive for existing shareholders, securing this capital extends the company's operational runway and supports its strategic development initiatives. The offering follows a preliminary announcement and indicates the company is actively moving forward with securing its financial future amidst a period of high corporate activity.
At the time of this filing, NBTX was trading at $40.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $3.64 to $57.14. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.